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INTRODUCTION
"Big data" has come to health care.' It is now widely agreed that
rapidly improving abilities to pull together and analyze massive
datasets will have the potential to transform health, health care, and
the health care system. Corporate websites tout the benefits of big
data-based technologies for improving patient care, expanding health
care access, and managing health care costs.2 Countless conferences
* @ 2014 Kristin Madison.
** Professor of Law and Health Sciences at Northeastern University. I thank Melissa
Jacoby for her suggestions, Frank Pasquale for helpful conversations, and Joan Krause
and Richard Saver for their contributions to the symposium for which this Article was
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symposium and for their improvements to this Article.
1. For a discussion of the definitions of big data, see Nicolas P. Terry, Protecting
Patient Privacy in the Age of Big Data, 81 UMKC L. REV. 385, 389-93 (2012).
2. See, e.g., Press Release, SAS, States Share Health Care Data Using SAS Claims
Analytics (Oct. 29, 2013), available at http://www.sas.com/news/preleases/healthcare-
claims-analytics.html (explaining how its products can help users "reduce costs and
improve quality by being better informed"); Big Data in Action-Healthcare, IBM,
http://www-01.ibm.com/software/datalbigdata/industry-healthcare.html (last visited May 7,
2014) (discussing big data-related health care projects); Healthcare Analytics, AVNET,
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have discussed the future of big data in health care.3 Consultants have
trumpeted the arrival of a big data "revolution" in the health
industry,' and the mainstream press,s policymakers,6 and legal
academics' have all now turned their attention to the topic.
Big data's transformative potential arises from the information it
could generate for many different types of users, including health care
providers, payers, patients, and regulators. Health care system
stakeholders make countless decisions every day that influence the
care that patients receive and ultimately patients' health. Those
decisions will nearly always turn on the information available to the
decision maker. What types of information exist, who is generating
that information, and how that information is gathered can have a
profound effect on the choices that are made.
In the health care setting, private actors have often played a
leading role in launching big data initiatives. Large, private insurers
and large, sophisticated health care providers are well positioned to
harness the power of big data. Private insurers have used their data to
test the relationship between medical treatments and patient
http://www.pepperweed.com/capabilities/healthcare-analytics.html (last visited May 7,
2014) (describing data management tools for health care providers).
3. See, e.g., Big Data Healthcare Forum, IQPC, http://www.bigdatahealthcare
summit.com/ (last visited May 7, 2014) (describing IQPE's 2013 big data conference);
Critical Data, MASS. INST. OF TECH., http://criticaldata.mit.edu/ (last visited May 7, 2014)
(describing MIT's 2014 big data conference); Bruce Goldman, Scientists Consider Potential
of Abundant Biomedical Data, STAN. SCH. OF MED. (May 28, 2013), http://med.stanford
.edu/ism/2013/may/bigdata-052813.html (describing the Big Data in Biomedicine
Conference at Stanford University); International Conference on Big Data and Analytics in
Healthcare, CENTER FOR HEALTH INFORMATICS, http://chi.comp.nus.edu.sg
/conference2013/ (last visited May 7, 2014) (describing the 2013 conference).
4. See generally PETER GROVES ET AL., CTR. FOR U.S. HEALTH SYs. REFORM, THE
'BIG DATA' REVOLUTION IN HEALTHCARE: ACCELERATING VALUE AND INNOVATION
(Jan. 2013), available at http://www.mckinsey.com/insights/health-systems/-/media
/7764A72F70184C8EA88D805092D72D58.pdf (describing the opportunities associated
with the growth of big data in health care).
5. See, e.g., Kelly Kennedy, Analysis of Huge Data Sets Will Reshape Health Care,
USA TODAY (Nov. 24, 2013), http://www.usatoday.com/story/news/nation/2013/11/24/big-
data-health-care/3631211/; Steve Lohr, Big Data Is Opening Doors, but Maybe Too Many,
N.Y. TIMES (Mar. 23, 2013), http://www.nytimes.com/2013/03/24/technology/big-data-and-
a-renewed-debate-over-privacy.html?pagewanted=all& r=0; Karen Weintraub, Firm
Hopes Big Data Can Personalize Health Care, BOS. GLOBE (May 13, 2013), http://www
.bostonglobe.com/business/2013/05/12/personalized-medicine-goal-big-data-
scientist/28gTkXjCDj6Zh6KP5tpNBO/story.html.
6. See, e.g., BIPARTISAN POLICY CTR., A POLICY FORUM ON THE USE OF BIG
DATA IN HEALTH CARE (2013), available at http://bipartisanpolicy.org/sites/default/files
/Use%20of%2OBig%2OData%20in%2OHealth%20Care.pdf.
7. See, e.g., Frank Pasquale, Grand Bargains for Big Data: The Emerging Law of
Health Information, 72 MD. L. REV. 682, 682-88 (2013) (discussing policy implications of
big data in health care); Terry, supra note 1, at 389-93 (same).
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outcomes8 and to engage in systematic study of cost trends.' Private
health care providers have looked to big data as a tool for improving
their patient care 0 and general operations." One of the biggest
holders of big data, however, is the federal government, which
processes over one billion health care claims each year for Medicare
alone.12 If the data embodied within these claims could be
transformed into useful information, the data would have the
potential to affect countless health care decisions made all over the
United States.
The federal government is more than just a big data repository,
however; it has become a data steward." The term "data
stewardship" can have many meanings, and it is sometimes associated
with the responsibility for protecting the integrity and confidentiality
of data.14 This is certainly one task that the federal government has
taken on, both with respect to its own programs and with respect to
data held by other regulated entities. Many health policy and law
8. See, e.g., Press Release, Aetna, Aetna Innovation Labs Focuses on Programs that
Measurably Improve Patient Outcomes (Aug. 27, 2012), available at http://newshub.aetna
.com/press-release/aetna-innovation-labs-focuses-programs-measurably-improve-patient-
outcomes (describing how Aetna Innovation Labs would work with a data analytics
company to test interventions for metabolic syndrome and quoting Aetna's chief medical
officer as stating that "[tihis 'big data' approach should be enormously helpful as we
introduce new interventions, letting us quickly identify what works, what doesn't, and
rapidly adjust as appropriate").
9. See Terry, supra note 1, at 409 (describing Health Care Cost Institute initiative);
see also About HCCI, HEALTH CARE COST INST., http://www.healthcostinstitute.org
/about (last visited May 7, 2014) (describing HCCI's mission of providing information
about health care utilization and costs).
10. See Merrill Goozner, Mayo Using Big Data, Digitized Know-How to Improve Care
and Extend Its Reach, MODERN HEALTHCARE (Dec. 7, 2013), http://www.modernhealth
care.com/article/20131207/magazine/312079956/mayo-using-big-data-digitized-know-how-
to-improve-care-and-extend.
11. See Terry, supra note 1, at 409 (describing big data initiatives).
12. See U.S. DEP'T OF HEALTH & HUMAN SERVS., Medicare Fee-for-Service,
PAYMENT ACCURACY, http://www.paymentaccuracy.gov/programs/medicare-fee-service
(last visited May 7, 2014).
13. To a lesser extent, state governments and other public and private entities have
also become data stewards. Given the extent of the federal government's ongoing data-
related activities, however, this Article will focus on federal initiatives in this area.
14. See, e.g., SUSAN BAIRD KANAAN & JUSTINE M. CARR, U.S. DEP'T OF HEALTH &
HUMAN SERVS., HEALTH DATA STEWARDSHIP: WHAT, WHY, WHO, How 1 (Sept. 2009),
available at http://www.ncvhs.hhs.gov/0909301t.pdf (defining "health data stewardship" as
"a responsibility ... to ensure the knowledgeable and appropriate use of data derived
from individuals' personal health information" and highlighting as "essential practices and
principles ... transparency about use; ... security safeguards and controls; de-
identification (when relevant); data quality, including integrity, accuracy, timeliness, and
completeness; limits on use, disclosure, and retention; oversight of data uses;
accountability; and enforcement and remedies").
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scholars, including Nicolas Terry, Frank Pasquale, Barbara Evans,
Deven McGraw, and Alice Leiter, have explored the implications of
current federal privacy and confidentiality laws in a world of big
data. 5 The work of these authors and others makes clear that
addressing concerns related to privacy and confidentiality is a critical
step in efforts to take full advantage of the promise of big data. Many
individuals value privacy in the health care sphere and may be
reluctant to share information if it is at risk of being disseminated too
widely. To address the concerns of such patients, policy makers and
others may seek to limit the collection, aggregation, and use of
patient data, or they may instead seek to develop robust privacy and
confidentiality policies that offer the protections some patients prize.
While privacy and confidentiality issues are important and need
to be addressed, this Article looks beyond them to consider the
broader responsibilities associated with data stewardship. One of the
meanings of "steward" is "one who actively directs affairs"16
stewards manage things. In recent years, through its laws, policies,
and programs, the federal government has taken on an increasingly
important role in managing the flow of health-related data. By doing
so, it has affected health care decision making and accelerated the
process of health care reform.
Part I of this Article explains that one of the federal
government's most important functions as a data steward has been to
make data bigger. Most obviously, the government adds to big data
through the generation and sharing of claims data from Medicare.
But it also expands data in myriad other ways; through numerous
recent initiatives, the federal government has served as a data
collector, aggregator, facilitator, and funder.
Part II suggests that at the same time, federal agencies have also
sought to make data smaller. While amassing data can be an
important first step in generating the information critical for health
15. See generally Barbara J. Evans, The Ethics of Postmarketing Observational Studies
of Drug Safety Under Section 505(o) (3) of the Food, Drug, and Cosmetic Act, 38 AM. J.L.
& MED. 577 (2012) (discussing HIPAA's impact on pharmaceutical companies' use of
claims data and electronic health records to conduct postmarketing observational studies);
Deven McGraw & Alice Leiter, A Policy and Technology Framework for Using Clinical
Data to Improve Quality, 12 HOUs. J. HEALTH L. & POL'Y 137 (2012) (discussing
implications of HIPAA, the federal Common Rule, and other laws for the use of
electronic health records to improve health care quality); Pasquale, supra note 7
(emphasizing the importance of well-designed intellectual property and privacy laws and
policies to ensure that the promise of health information technology is realized); Terry,
supra note 1 (describing changes needed in law and policy to protect patient privacy in an
era characterized by the growth of big data).
16. MERRIAM-WEBSTER'S COLLEGIATE DIcrIONARY 1224(11th ed. 2003).
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care reform, these data need to be analyzed and distilled before they
can be used effectively by health system stakeholders. Such analysis is
particularly challenging for patients, and the federal government has
taken numerous steps to make information for patients both
understandable and actionable. Part II examines several examples of
programs that help patients tackle complex decision making,
including the Patient-Centered Outcomes Research Institute
("PCORI") and the public posting of health care quality metrics.
Part III argues that while the efforts to make data bigger and
smaller have done much to lay the foundation for improved decision
making by all health care stakeholders-including payers, providers,
and patients-more remains to be done to improve decision making
by one other key health care system stakeholder: the government
itself. As data stewards, health care regulators should ensure that they
manage data in such a way as to better inform their own regulatory
decisions. Some initiatives in this area are already underway," but
health regulators, and, by extension, patients and taxpayers, would
likely benefit from focusing more attention to efforts to build an
evidence base for regulatory and programmatic interventions. Such
efforts will often involve making data bigger and may sometimes
involve making data smaller. Ultimately, however, they must include
a systematic effort to remake data.
I. MAKING DATA BIGGER
While the term "big data" is of relatively recent vintage,'" it has
arguably been integral to health care for many years. Data are a
critical input into many aspects of the health care delivery system.
The claims submitted to Medicare, Medicaid, and other public
programs and private insurers are used not just to perform these
entities' core payment functions but also to manage their broader
operations.19 Data extracted from these claims have also long been
17. See infra Part III.
18. See Francis X. Diebold, A Personal Perspective on the Origin(s) and
Development of "Big Data": The Phenomenon, the Term, and the Discipline 2 (Nov.
2012) (unpublished manuscript), available at http://www.ssc.upenn.edu/-fdiebold/papers
/paper112/DieboldBigData.pdf (describing the origins of the term).
19. See JANE HYATT THORPE, ERICA PEREIRA & SARA ROSENBAUM, GEORGE
WASHINGTON UNIV. MED. CTR., RELEASING MEDICARE CLAIMS DATA TO SUPPORT
QUALITY IMPROVEMENT INITIATIVES: LEGAL BARRIERS AND OPPORTUNITIES 3 (2010),
available at http://www.rwjf.org/content/dam/web-assets/2010/03/releasing-medicare-
claims-data-to-support-quality-improvement-in (noting that Medicare statute authorizes
release of Medicare data for research, demonstrations, and Medicare's Quality
Improvement Organizations).
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used by providers, researchers, and others seeking to learn more
about health and health care delivery.2 0 But the sheer volume of these
data, especially when combined with limited computing capacity, has
often meant that users, as a practical matter, could perform analyses
with only a subset of potentially useful data.21
In this era of big data, however, the technical constraints on
computing have loosened, allowing data to be more easily collected,
stored, and analyzed. The lower cost associated with these tasks has
allowed data to get even bigger and has made data-intensive analyses
much more feasible in many settings.2 2 Entities in a position to collect
data as part of their operations, such as payers and providers, are
capable of collecting and storing more data than ever before, 23 and
data not systematically collected previously-such as data about
purchasing patterns-can be gathered. These data can inform product
development, marketing, community health needs assessments,
health care quality evaluation, health regulation, and research in the
areas of medicine, health care, and public health.24
The federal government has worked to expand the availability of
data that could be useful for many of these functions. In addition to
20. See, e.g., DENISE LOVE, WILLIAM CUSTER & PATRICK MILLER, THE
COMMONWEALTH FUND, ALL-PAYER CLAIMS DATABASES: STATE INITIATIVES TO
IMPROVE HEALTH CARE TRANSPARENCY 4 (2010), available at http://www
.commonwealthfund.org/-/media/Files/Publications/Issue%2Briefl2010/Sep/1439_Love_a
llpayer claims databases ib v2 (describing uses of state all-payer claims databases and
noting that they "bring information on cost, quality, and administration to a wide variety
of healthcare constituents: consumers, policymakers, researchers, employers, public health
departments, commercial payers, providers, and others").
21. See Silvia Piai & Massimiliano Claps, Bigger Data for Better Healthcare 1 (IDC
Health Insights, White Paper No. IDCWP25V, Sept. 2013), available at http://www.intel
.com/content/dam/www/public/us/en/documents/white-papers/bigger-data-better-
healthcare-idc-insights-white-paper.pdf (describing vast growth of data over time and
stating that "in practice only 3% of potentially useful data is tagged and even less is
analyzed").
22. See THOMAS M. LENARD & PAUL H. RUBIN, THE BIG DATA REVOLUTION:
PRIVACY CONSIDERATIONS 1 (2013), available at https://www.techpolicyinstitute.org/files
/lenardrubinjthebigdatarevolutionprivacyconsiderations.pdf ("The Information
Technology revolution has produced a data revolution-now commonly referred to as 'big
data'-in which massive amounts of data can be collected, stored and analyzed at
relatively low cost.").
23. See id.
24. For some examples of data-intensive initiatives that preceded the popular use of
the term "big data," see Kristin Madison, ERISA and Liability for Provision of Medical
Information, 84 N.C. L. REV. 471, 502-06 (2006) [hereinafter Madison I]. For a discussion
of some of the implications of improved data processing abilities for regulation, see
generally Kristin Madison, Regulating Health Care Quality in an Information Age, 40 U.C.
DAVIS L. REV. 1577 (2007) [hereinafter Madison II].
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generating and sharing its own data, the federal government has acted
as a data collector, data aggregator, data facilitator, and data funder.
A. Federal Government as Data Generator
The federal government continues to contribute significantly to
the growth of big data through its role as a data generator, and
equally importantly, through sharing of the data it generates. The
Medicare program makes much of its data available in various forms
to researchers and the public.25 Given patient privacy concerns,' 6
there are limits to how much federal claims data can be shared.
Recent developments suggest an increased willingness to make claims
data more widely available, however.27 One example is that for many
years, an injunction blocked the release of Medicare physician claims
to the public based on the implications of such a release for physician
privacy.28 This injunction was lifted in 2013,29 and the Centers for
Medicare and Medicaid Services ("CMS") subsequently solicited
public comment about the policies that should be adopted with
respect to the release of physician claims data.30 In 2014, CMS
announced a new policy under which it would determine on a case-
by-case basis whether physician payment data could be released in
response to Freedom of Information Act requests.1 It subsequently
released claims data for over 880,000 health care providers.32
25. See Files for Order - General Information, CENTERS FOR MEDICARE &
MEDICAID SERVICES, https://www.cms.gov/Research-Statistics-Data-and-Systems[Files-
for-Order/FilesForOrderGenlnfoindex.html (last updated Apr. 23, 2013) (listing
identifiable data files, limited data set files, and non-identifiable data files available for
use).
26. See supra note 15 and accompanying text.
27. See Marilyn Tavenner & Niall Brennan, CMS Progress Towards Greater Data
Transparency, HEALTH AFF. (July 31, 2013), http://healthaffairs.orgfblog/2013/07/31/cms-
progress-towards-greater-data-transparency/ (detailing recent transparency initiatives).
28. See Fla. Med. Ass'n, Inc. v. Dep't of Health, Educ., & Welfare, 947 F. Supp. 2d
1325, 1329 (M.D. Fla. 2013) (describing injunction).
29. See id. at 1357.
30. Request for Public Comments on the Potential Release of Medicare Physician Data,
CENTERS FOR MEDICARE & MEDICAID SERVICES (Aug. 6, 2013), http://downloads.cms
.gov/files/Request-for-Public-Comment-rePhysician-Data-8-6-2013.pdf.
31. Modified Policy on Freedom of Information Act Disclosure of Amounts Paid to
Individual Physicians Under the Medicare Program, 79 Fed. Reg. 3205 (Jan. 17,2014).
32. Press Release, U.S. Dep't of Health & Human Servs., Historic Release of Data
Gives Consumers Unprecedented Transparency on the Medical Services Physicians
Provide and How Much They Are Paid (Apr. 19, 2014), available at http://www.hhs.gov
/news/press/2014pres/04/20140409a.html.
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B. Federal Government as Data Collector
Medicare claims data are generated as a byproduct of program
operations, not as a result of a deliberate effort to expand data
available for researchers or policy makers. The federal government
has undertaken a number of initiatives, however, to collect other
types of health-related information. Health care researchers often
rely on data collected through the census and a number of other
important surveys conducted through the Centers for Disease Control
and Prevention ("CDC") and other agencies. Commonly used
surveys include the National Health Interview Survey,33 the National
Health and Nutrition Examination Survey,34 the Medicare Current
Beneficiary Survey, 5 and the Medical Expenditure Panel Survey. 6
One of the fastest-growing forms of federal data collection,
however, involves information that is associated with public insurance
programs but goes beyond the bare-bones fee-for-service claims data
that are at the traditional core of program operations.37 One example
is health care quality data. While insurers, accreditation
organizations, state governments, and other entities may all seek
quality-related information from providers,3 8 the federal government
has often acted as a leader in this area. In 2003, Congress altered
33. National Health Interview Survey, CENTERS FOR DISEASE CONTROL &
PREVENTION, http://www.cdc.gov/nchs/nhis.htm (last updated Dec. 30, 2013); see, e.g.,
Matthew Miller et al., Veterans and Suicide: A Reexamination of the National Death Index-
Linked National Health Interview Survey, 102 AM. J. PUB. HEALTH (SUPPLEMENT 1)
S154, S154-57 (2012).
34. National Health and Nutrition Examination Survey, CENTERS FOR DISEASE
CONTROL & PREVENTION, http://www.cdc.gov/nchs/nhanes.htm (last updated Jan. 15,
2014); see, e.g., Belinda L. Needham et al., Socioeconomic Status, Health Behavior, and
Leukocyte Telomere Length in the National Health and Nutrition Examination Survey,
1999-2002, 85 SOC. SCI. & MED. 1, 1-7 (2013).
35. Medicare Current Beneficiary Survey, CENTERS FOR MEDICARE & MEDICAID
SERVICES, http://www.cms.gov/Research-Statistics-Data-and-Systems[ResearchlMCBS
/index.html?redirect=/MCBS (last updated July 18, 2013); see, e.g., Jae Kennedy et al., The
Association Between Class of Antipsychotic and Rates of Hospitalization: Results of a
Retrospective Analysis of Data from the 2005 Medicare Current Beneficiary Survey, 31
CLINICAL THERAPEUTICS 2931, 2931-37 (2009).
36. Medical Expenditure Panel Survey, AGENCY FOR HEALTHCARE RES. &
QUALITY, http://meps.ahrq.gov/mepsweb/ (last visited May 7, 2014); see, e.g., Jaeyoung
Kim, Depression as a Psychosocial Consequence of Occupational Injury in the US Working
Population: Findings from the Medical Expenditure Panel Survey, 13:303 BMC PUB.
HEALTH, 2013, at 1, 2-9.
37. See THORPE, PEREIRA & ROSENBAUM, supra note 19, at 2 ("Medicare claims
data, like those maintained by private health insurers, are used primarily to pay claims.").
38. See Robert J. Panzer et al., Increasing Demands for Quality Measurement, 310 J.
AM. MED. ASS'N 1971, 1972-75 (2013) (describing many producers and users of health
care quality measures).
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Medicare payment formulas to encourage hospitals to participate in a
reporting system.39 Today, over 1,300 hospitals are participating in a
value-based purchasing program in which reimbursement levels are
tied to data the hospitals provide about quality, including infection
rates and mortality rates.4 Also included in the program are data
drawn from patient responses to surveys about their own
experiences.41
CMS collects quality-related information from other providers as
well. In 2006, physicians were given payment incentives to voluntarily
participate in a reporting system.42 By 2015, physicians covered by the
program will receive a reduction in payment if they do not
participate, and by 2017, all physicians who participate in Medicare
will be subject to the value-based payment modifier.43 CMS has
quality initiatives underway for home health agencies' and nursing
homes,45 and the Patient Protection and Affordable Care Act
("ACA") mandated the creation of quality reporting programs for
long-term care hospitals and hospice programs.4 6 As the federal
government moves away from a public insurance payment system
based only on the quantity of services rendered toward systems that
39. See Medicare Prescription Drug, Improvement, and Modernization Act of 2003,
Pub. L. No. 108-173, § 501(b), 117 Stat. 2066, 2289 (amending 42 U.S.C.
§ 1395ww(b)(3)(B)); see also Kristin M. Madison, From HCQIA to the ACA: The
Evolution of Reporting as a Quality Improvement Tool, 33 J. LEGAL MED. 63, 78-79
(2012) [hereinafter Madison III] (describing the history of federal reporting initiatives).
40. See Medicare Program, 78 Fed. Reg. 50,496, 50,678-80 (Aug. 19, 2013) (listing
hospital quality measures to be used in 2014 and 2015 value-based purchasing programs);
Patrick Conway, CMS Releases Latest Value-Based Purchasing Program Scorecard, CMS
BLOG (Nov. 14, 2013), http://blog.cms.gov/2013/11/14/cms-releases-latest-value-based-
purchasing-program-scorecard/ (reporting on hospital participation levels).
41. Medicare Program, 78 Fed. Reg. at 50,678-80 (listing patient experience measures
among quality measures used in program).
42. See Madison III, supra note 39, at 79.
43. See Physician Quality Reporting System (PQRS) Overview, CENTERS FOR
MEDICARE & MEDICAID SERVICES 1, 2-3, http://www.cms.gov/Medicare/Quality-
Initiatives-Patient-Assessment-Instruments/PQRS/Downloads/PQRS OverviewFact
Sheet 2013 08 06.pdf (last visited May 7, 2014); Value-Based Payment Modifier,
CENTERS FOR MEDICARE & MEDICAID SERVICES, http://www.cms.gov/Medicare
/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/valueBasedPayment
Modifier.html (last modified Dec. 23, 2013).
44. Home Health Quality Initiative, CENTERS FOR MEDICARE & MEDICAID
SERVICES, http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instru
ments/HomeHealthQualityInits/index.html (last modified Apr. 10, 2013).
45. Nursing Home Quality Initiative, CENTERS FOR MEDICARE & MEDICAID
SERVICES, http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instru
ments/NursingHomeQualitylnits/index.html (last modified Sept. 20, 2013).
46. See Patient Protection and Affordable Care Act § 3004, 42 U.S.C. § 1395ww(j),
(m) (2012).
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involve more careful examination of the nature of these services, the
pool of data available for analysis will necessarily expand.
C. Federal Government as Data Aggregator
Data generated in connection with Medicare and Medicaid are
likely to fit within most people's definitions of big data, given the size
and scope of these programs. But for many potential uses of big data,
these data are not big enough. The data are associated with
beneficiaries of these public programs, not the majority of Americans
who are privately insured,4 7 and claims data do not capture the full
wealth of data available in electronic medical records.4 Private
insurers and health care providers have access to vast stores of data
on millions of Americans that could help guide health care system
reform and support decision making among many system
stakeholders. Access to data would provide researchers and analysts
with a more comprehensive picture of health, health care, and health
care financing in the United States. There are many barriers to
sharing these data, including concerns (and laws) related to patient
privacy,49 proprietary interests in the data," and the transaction costs
involved in attempting to reach out to many different entities in our
fragmented health care system," but the federal government has
worked to overcome these barriers.
As an initial step, CMS has been able to promote aggregation by
releasing its data so that it can be added to data held by others. The
ACA required the release of Medicare claims data involving hospital
services, physician services, prescription drugs, and other services and
supplies to public and private entities seeking to pool these data with
47. CARMEN DENAVAS-WALT, BERNADETTE D. PROCTOR & JESSICA C. SMITH,
U.S. CENSUS BUREAU, INCOME, POVERTY, & HEALTH INSURANCE COVERAGE IN THE
UNITED STATES: 2012, at 26 tbl.8 (2013) (showing that in 2012, nearly sixty-four percent of
people had private coverage and that fifty-two percent had private coverage only).
48. See Panzer et al., supra note 38, at 1972-73 (discussing limitations of claims data
relative to "rich clinical data").
49. See Health Insurance Portability and Accountability Act (HIPAA) of 1996, Pub
L. No. 104-191, 0§ 261-264, 110 Stat. 1936, 2021-34 (codified as amended at 42 U.S.C.
§ 1320d (2012)); 45 C.F.R. pts. 160, 164 (2013) (governing privacy of individually
identifiable health information). See generally Terry, supra note 1 (discussing privacy
challenges in the age of big data).
50. Cf GROVES ET AL., supra note 4, at 12 (noting that big data innovations often
make use of proprietary data).
51. See, e.g., Michael F. Furukawa et al., Hospital Electronic Health Information
Exchange Grew Substantially in 2008-12, 32 HEALTH AFF. 1346, 1346 (2013) (discussing
challenges of sharing information across entities through health information exchanges).
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other data for the purposes of evaluating provider performance.5 2
These entities would be required to release the quality ratings to the
public.5 ' By facilitating the pooling of public and private data, this
provision would increase the information available about the
performance of individual providers, helping to address the data
limits that so frequently plague efforts to develop reliable provider
quality measures.54
Another way in which the federal government can engage in data
aggregation is by facilitating interactions among private entities. One
example of this approach is the Sentinel Initiative,5 under which "the
FDA seeks to create a scalable, efficient, extensible, and sustainable
system ... that leverages existing electronic health care data from
multiple sources to actively monitor the safety of regulated medical
products." 56 In the Food and Drug Administrative Amendments Act
of 2007," Congress required the Secretary of Health and Human
Services ("HHS") to work with "public, academic, and private
entities" to "develop validated methods for the establishment of a
postmarket risk identification and analysis system to link and analyze
safety data from multiple sources" that would include at least one
hundred million patients by 2012." The statute further requires the
creation of procedures that would allow for monitoring for adverse
drug events using federal data such as Medicare and Veterans Affairs
data as well as private sector data such as data from drug purchases
52. The statute applies to Medicare Part A, Part B, and Part D claims. Patient
Protection and Affordable Care Act § 10332, 42 U.S.C. § 1395kk(e) (2012); Availability of
Medicare Data for Performance Measurement, 76 Fed. Reg. 76,542, 76,567 (Dec. 7, 2011)
(codified at 42 C.F.R. pt. 401).
53. See 42 U.S.C. § 13955kk(e)(4)(C)(iv).
54. Limited data affect many efforts to measure provider quality, particularly at the
level of an individual provider. See, e.g., David J. Nyweide et al., Relationship of Primary
Care Physicians' Patient Caseload with Measurement of Quality and Cost Performance, 302
JAMA 2444, 2444 (2009) (concluding that "[r]elatively few primary care physician
practices are large enough to reliably measure 10% relative differences in common
measures of quality and cost performance among fee-for-service Medicare patients").
55. For a thorough discussion of the Sentinel Initiative and an evaluation of the
possibility that the FDA might be able to require participation in it, rather than merely
convene voluntary participants, see generally Barbara J. Evans, Authority of the Food and
Drug Administration to Require Data Access and Control Use Rights in the Sentinel Data
Network, 65 FOOD & DRUG L.J. 67 (2010).
56. U.S. FOOD & DRUG ADMIN., MINI-SENTINEL, Principles and Policies 1 (Nov.
2013), available at http://mini-sentinel.org/work-products/AboutUs/Mini-Sentinel-
Principles-and-Policies.pdf.
57. Food and Drug Administration Amendments Act of 2007 § 905(a), Pub. L. No.
110-85, 121 Stat. 823, 944 (codified as amended in scattered sections of 21 U.S.C.).
58. 21 U.S.C. § 355(k)(3)(B) (2012).
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and health insurance claims.59 The procedures must also permit the
identification of and reporting on trends and patterns of adverse drug
events.' Under a pilot program, the mini-Sentinel, the data would not
be joined into a single database, but instead would be held by the
institutions in which the data originated and then transmitted across
"a distributed data network that is linked by a coordinating center."6 1
Participants in this initiative include numerous entities affiliated with
major insurers.62
Another example of a federal aggregation effort is the eMERGE
Network, an initiative funded by the National Institutes of Health
("NIH") that aims to "develop, disseminate, and apply approaches to
research that combine DNA biorepositories with electronic medical
record ... systems for large-scale, high-throughput genetic research"
that "brings together researchers ... from leading medical research
institutions across the country."63 The network is intended to foster
collaboration in genetic research through shared expertise, access to
shared tools, and the use of pooled data.' Participants in the network
agree to submit genetic data to a coordinating center that will then
combine the data with the network dataset and submit them to the
database of Genotypes and Phenotypes, which makes individual-level
genetic data available to researchers."
Another example of an NIH-sponsored data aggregation
program is the Health Care Systems Research Collaboratory. Like
the eMERGE Network, this program features a coordinating center
59. See id. § 355(k)(3)(C)(III).
60. See id. § 355(k)(3)(C)(IV)-(V).
61. Efthimios Parasidis, Patients over Politics: Addressing Legislative Failure in the
Regulation of Medical Products, 2011 Wis. L. REV. 929, 971-73 (2011). For a brief
description of how data are shared, see U.S. FOOD & DRUG ADMIN., Data Activities,
MINI-SENTINEL, http://mini-sentinel.org/data-activities/ (last visited May 7, 2014).
62. U.S. FOOD & DRUG ADMIN., Collaborators, MINI-SENTINEL, http://mini-sentinel
.org/about-us/collaborators.aspx (last visited May 7, 2014).
63. NAT'L INSTS. OF HEALTH, Electronic Medical Records and Genomics (eMERGE)
Network, NAT'L HUMAN GENOME RESEARCH INST., http://www.genome.gov/27540473
(last updated Aug. 29, 2013).
64. See For Researchers, EMERGE NETWORK, http://emerge.mc.vanderbilt.edu
/researchers (last visited May 7, 2014). For a detailed description of the eMERGE
Network, see Catherine A. McCarty et al., The eMERGE Network: A Consortium of
Biorepositories Linked to Electronic Medical Records Data for Conducting Genomic
Studies, 4:13 BMC MED. GENOMICS 2011, at 2.
65. See Criteria for Affiliate Membership, EMERGE NETWORK, http://emerge
.mc.vanderbilt.edu/qflpubliclEMERGENetworkCriteriafor_AffiliateMembership.pdf
(last updated Sept. 28, 2011) (describing criteria for network participation); NAT'L CTR.
FOR BIOTECH. INFO., dbGaP Overview, DBGAP, http://www.ncbi.nlm.nih.gov/projects
/gap/cgi-binlabout.html (last visited May 7, 2014).
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that facilitates the dissemination of "data, tools, and resources."'
Members of the Collaboratory, which currently include organizations
such as the Duke Clinical Research Institute, the Harvard Pilgrim
Health Care Institute, and the Group Health Research Institute,
"work with the NIH to produce, document, and disseminate
standards, and to create durable infrastructure that facilitates
multicenter studies and reuse of data."' One Collaboratory trial
involves a study of the impact of hemodialysis sessions of at least four
hours; it will involve several hundred dialysis facilities where care is
routinely provided, and it will use data routinely collected as part of
care provision.' One goal of the Collaboratory is to make better use
of routinely collected data in real-world care settings.69
D. Federal Government as Data Facilitator
When the federal government supports aggregation through
programs such as the eMERGE Networko or the Collaboratory,
what it is really doing is facilitating interactions among private
entities.72 By exercising leadership and designating an entity to serve
in a coordinating role, it helps interested institutions surmount
barriers that might otherwise prevent collaboration and the sharing of
data. By contrast, other federal initiatives accelerate the growth of
data by facilitating their development and dissemination.
The federal government directly develops data when it collects
data as part of its own operations or mandates reporting as part of its
regulatory functions.73 At the same time, it may facilitate data growth
among private entities. One of the best examples of this phenomenon
is the federal effort to promote the growth of electronic health
66. About Us, NAT'L INSTS. OF HEALTH COLLABORATORY, https://www.nihcol
laboratory.org/about-us/Pages/default.aspx (last visited May 7, 2014).
67. Id.
68. See Pragmatic Trials in Maintenance Hemodialysis, NAT'L INSTS. OF HEALTH
REPORT, http://projectreporter.nih.gov/project-info-description.cfm?aid=8466041&icde
=19851725 (last updated Mar. 31, 2014); Time to Reduce Mortality in End-Stage Renal
Disease (TiME), NAT'L INSTS. OF HEALTH COLLABORATORY, https://www.nihcol
laboratory.org/demonstration-projects/Pages/TIME.aspx (last visited May 7, 2014).
69. See Eric B. Larson, Building Trust in the Power of "Big Data" Research to Serve
the Public Good, 309 JAMA 2443, 2444 (2013) (describing the NIH Collaboratory and
other big data-oriented initiatives).
70. See supra notes 63-65 and accompanying text.
71. See supra notes 66-69 and accompanying text.
72. For a discussion of how it is also funding these interactions, see infra notes 90-93
and accompanying text.
73. See supra Part I.B.
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records (and the data they contain) through the HITECH Act74 and
the associated "meaningful use" regulations." The HITECH Act
sought to vastly expand the use of electronic health records through
what might be thought of as three fundamental strategies: subsidies,
standards, and supports.7 6 It made billions of dollars in payments-
more than $40,000 per physician-available to providers who adopt
and use electronic health records." To receive the rewards, providers
are required to meet a series of objectives, such as recording a certain
percentage of patients' demographic data as structured data or
submitting a certain percentage of prescriptions electronically.7 8
These objectives are collectively known as "meaningful use"
requirements." They are complemented by a set of standards by
which electronic health record systems will be certified as supporting
compliance with these requirements."o Supports for the expansion of
electronic health records include workforce training programs and
regional extension centers that offer assistance to health care
providers seeking to make the transition to electronic health
records.8'
Changing the medium of medical record storage from paper to
electronic media does not in itself make more data available to users.
But the meaningful use regulations require that records be used for
certain purposes, such as reporting clinical quality measures or
maintaining active medication lists, which will likely mean that more
74. Health Information Technology for Economic and Clinical Health (HITECH)
Act, Pub. L. No. 111-5, 123 Stat. 226 (2009) (codified as amended in scattered sections of
42 U.S.C.).
75. See 42 C.F.R. § 495.6 (2013) (establishing meaningful use objectives); 45 C.F.R.
§ 170.314 (establishing electronic health record certification criteria).
76. See HITECH Act, HEALTHIT.GOV, http://www.healthit.gov/policy-researchers-
implementers/hitech-act (last visited May 7, 2014) (noting that the HITECH Act "seeks to
improve American health care delivery and patient care through an unprecedented
investment in Health IT" and that its "programs collaboratively collectively build the
foundation for every American to benefit from an EHR").
77. See David Blumenthal & Marilyn Tavenner, The "Meaningful Use" Regulation for
Electronic Health Records, 363 NEW ENG. J. MED. 501, 501 (2010).
78. See id.; EHR Incentives & Certification: How to Attain Meaningful Use,
HEALTHIT.GOV, http://www.healthit.gov/providers-professionals/how-attain-meaningful-
use (last visited May 7, 2014).
79. See Blumenthal & Tavenner, supra note 77, at 501.
80. See EHR Incentives & Certification, supra note 78 (describing the role of
certification); see also 45 C.F.R. § 170.314 (establishing electronic health record
certification criteria).
81. See Melinda Beeuwkes Buntin, Sachin H. Jain & David Blumenthal, Health
Information Technology: Laying the Infrastructure for National Health Reform, 29
HEALTH AFF. 1214, 1216 (2010).
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data will be captured initially than might otherwise be the case.2
Moreover, the requirements associated with HITECH will ensure
that, once captured, the data will flow more easily to other health-
related entities. For example, the Stage 2 meaningful use criteria push
data sharing forward by including as objectives the ability to submit
electronic data to immunization registries, cancer registries, and
public health agencies.83 HITECH also provided more than a half
billion dollars to support the development of health information
exchanges, through which electronic data could flow from one entity
to another.' Improved technologies that allow for less costly access to
data can potentially support many different activities, including
health care quality monitoring, medical research, and public health
surveillance.
The federal government can also facilitate the dissemination of
data through programs that make data easier to find and access. The
most prominent example of this kind of project is the website
HealthData.gov, which brings together over a thousand health-
related datasets, from Medicare cost report data to CDC data to Food
and Drug Administration ("FDA") recall information.5 The purpose
of the website is to "mak[e] high value health data more accessible to
entrepreneurs, researchers, and policy makers in the hopes of better
health outcomes for all."86 The website provides access to data not
previously available and seeks to offer data in a form that is
"machine-readable, downloadable and accessible via application
programming interfaces" so that it can be more easily used.
In addition, just this year, CMS announced these data would be
available more rapidly and at a lower cost through a new initiative,
82. See Medicare & Medicaid EHR Incentive Program: Meaningful Use Stage 1
Requirements Overview, CENTERS FOR MEDICARE & MEDICAID SERVICES (2010),
http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms
/Downloads/MUStagelReqOverview.pdf (describing meaningful use stage 1 objectives
and measures).
83. The immunization registry submission capability is a "core" (required) measure
for eligible professionals, while the cancer and public health reporting measures are part
of a broader menu of six objectives from which providers are required to choose three. See
Ctrs. for Medicare & Medicaid Servs., Eligible Professional's Guide to Stage 2 of the EHR
Incentive Programs 1, 14, 33 (2013), http://www.cms.gov/Regulations-and-Guidance
/Legislation/EHRIncentivePrograms/Downloads/Stage2_Guide EPs_9_23_13.pdf.
84. See Buntin, Jain & Blumenthal, supra note 81, at 1217.
85. See Data, HEALTHDATA.GOV, http://www.healthdata.gov/dataset/search (last
visited May 7, 2014) (cataloging available datasets).
86. Unleashing the Power of Data and Innovation to Improve Health,
HEALTHDATA.GOV, http://www.healthdata.gov/unleashing-power-data-and-innovation-
improve-health (last visited May 7, 2014).
87. Id.
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the Virtual Data Research Center." Given the traditionally heavy
reliance of health services researchers on Medicare claims data,8 9 this
initiative is likely to further pr'omote the publication of studies
examining the U.S. health care delivery system.
E. Federal Government as Data Funder
One of the most important ways that the federal government
makes big data bigger is through direct funding of projects involving
data generation, collection, or dissemination. In recent years, annual
congressional appropriations for the NIH, which funds health
research, have been in the range of thirty billion dollars.' The
Agency for Healthcare Research and Quality conducts and sponsors
research on health care delivery.9 1 Many of the previously discussed
initiatives that involved private entities were supported by grant
funding,92 and the billions of dollars appropriated under the HITECH
Act93 undoubtedly have accelerated the adoption of electronic health
records.94 Federal funding has played an important role in expanding
the availability of data.
88. See Niall Brennan, Virtual Research Data Center Offers Secure Timely Access to
Data at Lower Cost, CMS BLOG (Nov. 12, 2013), http://blog.cms.gov/2013/11/12/virtual-
research-data-center-offers-secure-timely-access-to-data-at-lower-cost/.
89. See id. ("Studies that help us better understand the healthcare ecosystem are
published almost weekly in major medical journals based on CMS data.").
90. See NAT'L INSTS. OF HEALTH, History of Congressional Appropriations, Fiscal
Years 2000-2012, NIH OFFICE OF BUDGET 1, http://officeofbudget.od.nih.gov/pdfs
/FY12/Approp.%20History%20by%201C)2012.pdf.
91. See AHRQ Employment Opportunities, AGENCY FOR HEALTHCARE RES. &
QUALITY, http://www.ahrq.gov/about/careers/index.html (last visited May 7, 2014).
92. See, e.g., The Electronic Medical Records and Genomics (eMERGE) Network,
Phase II Coordinating Center (U01), NAT'L INSTS. OF HEALTH, http://grants.nih.gov
/grants/guide/rfa-files/RFA-HG-10-010.html (last visited May 7, 2014) (announcing federal
funding for eMERGE network); Funding Opportunities, NAT'L INSTS. OF HEALTH,
http://commonfund.nih.gov/hcscollaboratory/grants (last visited May 7, 2014) (listing
previous grant announcements for the Health Care Systems Research Collaboratory).
93. See Blumenthal & Tavenner, supra note 77, at 501 (noting that incentive payments
will total up to $27 billion).
94. See CHUN-JU HSIAO & ESTHER HING, NAT'L CTR. FOR HEALTH STATISTICS,
U.S. DEP'T OF HEALTH & HUMAN SERVS., DATA BRIEF: USE AND CHARACTERISTICS
OF ELECTRONIC HEALTH RECORD SYSTEMS AMONG OFFICE-BASED PHYSICIAN
PRACTICES: UNITED STATES, 2001-2013, at 1 (2014), available at http://www.cdc.gov/nchs
/dataldatabriefstdbl43.pdf (documenting the recent rise in electronic health record
adoption rate and the large fraction of physicians participating in federal incentive
programs).
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II. MAKING DATA SMALLER
Federal agencies are uniquely positioned to foster the growth of
data, given the nature of their services and the scope of their
authority. The traditional governmental role as a provider of public
goods95 is consistent with the federal role in supporting research
activities including data collection, analysis, and dissemination. The
federal role as a sponsor of public health insurance covering a large
fraction of the American population will often mean that federal
agencies will play a central role in efforts to secure access to large,
comprehensive datasets. But these are not the only tasks that federal
entities have taken on. While much federal effort is focused on
making data bigger, federal agencies have also sought to make data
smaller. In recent years, the government's enthusiasm for promoting
wider availability of data has been matched by a zest for distilling it
into smaller, more usable forms.
The idea that data stewardship might involve efforts to make
data smaller makes perfect sense in a policy and practice environment
characterized by an emphasis on patient-centeredness. The concept of
patient-centeredness, identified by the Institute of Medicine in a 2001
report as one of six goals for health care delivery, involves a focus on
the "needs, values, and expressed preferences of the individual
patient," and patient education is often mentioned as an important
dimension of patient-centered care.9 6 Initiatives that seek to
communicate health and health care-related information in a way that
patients can understand and use are therefore consistent with the goal
of patient-centeredness. Patients frequently face daunting challenges
in navigating the complexities of the health care system at a time of
particular personal vulnerability.97  To be effective, the
communication process will therefore often involve simplifying the
presentation of information, tailoring information to individual
95. See REXFORD E. SANTERRE & STEPHEN P. NEUN, HEALTH ECONOMICS:
THEORIES, INSIGHTS, AND INDUSTRY STUDIES 230 (3rd ed. 2004) ("One legitimate
function of government is to provide public goods .... Government ensures that public
goods are produced in either the private or public sector and collects the necessary
funding through taxation.").
96. See INST. OF MED., CROSSING THE QUALITY CHASM: A NEw HEALTH SYSTEM
FOR THE 21ST CENTURY 40 (2001) (stating that "health care should be safe, effective,
patient-centered, timely, efficient, and equitable"); id. at 48-49 (describing aspects of
patient-centeredness); Kristin Madison, Patients As "Regulators"? Patients' Evolving
Influence Over Health Care Delivery, 31 J. LEGAL MED. 9, 13-14 (2010) [hereinafter
Madison IV] (exploring various definitions of patient-centeredness).
97. See Mark A. Hall & Carl E. Schneider, Patients as Consumers: Courts, Contracts,
and the New Medical Marketplace, 106 MICH. L. REV. 643, 650-59 (2008) (discussing how
illness affects patients' ability to navigate medical marketplaces).
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patient needs and preferences, and targeting information directly to
the patient, so that the information reaches and engages the patient.
Simplifying, tailoring, and targeting could all be thought of as ways of
making data smaller. A variety of federal initiatives have taken on
these tasks.
A. Patient Decision Aids
The ACA demonstrates both a commitment to patient-
centeredness and an associated emphasis on making data smaller."
As one commentary explains, the ACA "repeatedly refers to patient-
centeredness, patient satisfaction, patient experience of care, patient
engagement, and shared decision-making in its provisions."9 9 One
example of a provision fitting this description concerns patient
decision aids, which the ACA defines in part as "an educational tool
that helps patients . . . understand and communicate their beliefs and
preferences related to their treatment options, and to decide ... what
treatments are best."" The provision requires the creation of
standards against which decision aids will be evaluated and the
creation of a process for certifying those meeting the relevant
standards.'01 In addition, it calls for a program that would fund the
development of patient decision aids that would, among other things,
present up-to-date clinical evidence about the risks and benefits
of treatment options in a form and manner that is age-
appropriate and can be adapted for patients ... from a variety
of cultural and educational backgrounds to reflect the varying
needs of consumers and diverse levels of health literacy.102
In other words, the ACA embraces a federal policy goal of ensuring
that clinical information is made available to patients in a form
tailored to their needs. Thus, while the federal government helps
make data bigger by supporting clinical research,"1 it also helps make
98. See generally MICHAEL L. MILLENSON & JULIANA MACRI, URBAN INST., WILL
THE AFFORDABLE CARE Acr MOVE PATIENT-CENTEREDNESS TO CENTER STAGE?
(2012), available at http://www.urban.org/UploadedPDF/412524-will-the-affordable-care-
act.pdf.
99. Id. at 1.
100. 42 U.S.C. § 299b-36(b)(1) (2012). For a general discussion of decision support
tools, see Nadia N. Sawicki, Patient Protection and Decision-Aid Quality: Regulatory and
Tort Law Approaches, 54 ARIZ. L. REV. 621, 628-33 (2012).
101. See 42 U.S.C. § 299b-36(c).
102. Id. § 299b-36(d).
103. See supra notes 90-94 and accompanying text.
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data smaller by increasing the likelihood that research results are
delivered to patients in an easily usable format.
B. Patient- Centered Outcomes Research Institute
Another ACA program that falls within the "making data
smaller" category is the Patient-Centered Outcomes Research
Institute ("PCORI").'" PCORI has often been described as an
institution that sponsors comparative effectiveness research;0 it
funds studies that compare the effects of multiple approaches to
treating a particular disease or condition.106 As its official name
indicates, however, patients-not treatment methods-are at the very
center of its mission. PCORI describes its mission as "help[ing]
people make informed health care decisions, and improv[ing]
healthcare delivery and outcomes, by producing and promoting high
integrity, evidence-based information that comes from research
guided by patients, caregivers and the broader healthcare
community."" Its description of its vision reinforces the small data
nature of PCORI's work: "Patients and the public have information
they can use to make decisions that reflect their desired outcomes."'o
The information must be ultimately usable by patients, not just
researchers or medically trained clinicians, and it must take a form
that allows patients to understand its implications for the outcomes
they care about.
PCORI's early projects suggest a close adherence to this vision.
For example, one funded study will evaluate a toolkit that helps
clinicians identify "the type of treatment most likely to be successful
based on the different pain experiences reported by the patient,"10
104. See 42 U.S.C. § 1320e(b).
105. See, e.g., Alan M. Garber, How the Patient-Centered Outcomes Research Institute
Can Best Influence Real-World Health Care Decision Making, 30 HEALTH AFF. 2243, 2243
(2011) (describing PCORI as "created to set priorities and fund comparative effectiveness
research while ensuring the production of high-quality studies that adhere to rigorous
standards").
106. See, e.g., PATIENT-CENTERED OUTCOMES RESEARCH INST., NATIONAL
PRIORITIES FOR RESEARCH AND RESEARCH AGENDA 3, 8 (2012), available at http://
www.pcori.org/assets/PCORI-National-Priorities-and-Research-Agenda-2012-05-21-
FINAL1.pdf (listing as the first research priority "[c]omparing the effectiveness and safety
of alternative prevention, diagnosis, and treatment options to see which ones work best for
different people with a particular health problem").
107. Mission and Vision, PATIENT-CENTERED OUTCOMES RES. INST., http://www
.pcori.org/about-us/mission-and-vision/ (last visited May 7, 2014).
108. Id.
109. Rachael Fleurence et al., How the Patient-Centered Outcomes Research Institute Is
Engaging Patients and Others in Shaping Its Research Agenda, 32 HEALTH AFF. 393, 395
(2013).
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while another will "provide culturally tailored information for Latina
adolescents and their parents to help in making decisions on whether
or not to receive the human papilloma-virus vaccination.""o The
choices PCORI has made evidence a federal commitment to tailoring
information to the needs of individual patients.
The patient decision aid and PCORI examples illustrate a
common phenomenon: efforts to make data smaller often accompany
efforts to make data bigger. PCORI will promote the growth of
comparative effectiveness research in general but will also target
research toward the populations that most benefit from it. Medical
research continues to produce new results, but patient decision aids
are critical to ensuring that individuals use results appropriately.
C. Meaningful Use Regulations
The meaningful use regulations might also be said to fit the
small-data-as-counterpart-of-big-data mold. The HITECH statute
sought to vastly expand the adoption of electronic health records
through subsidies, standards, and supports, a step that will facilitate
future research, including big data projects."' But the meaningful use
standards that accompanied the HITECH statute would
simultaneously help to make data smaller by promoting the sharing of
data tailored to an individual patient's needs.
Like PCORI and patient decision aids, meaningful use
regulations are guided by the concept of patient-centeredness."I
These regulations encourage medical professionals to reach out to
patients based on patients' likely needs. According to the objectives
specified by the regulations, medical professionals should have the
ability to use their electronic health records to generate lists of
patients by condition, which would permit better monitoring and
follow-up with patients."' Professionals should be able to identify
patients who would benefit from reminders; they should also be able
110. Id.
111. See supra notes 74-84 and accompanying text.
112. See Farzad Motashari & Marilyn Tavenner, Stage 2 Meaningful Use NPRM Moves
Toward Patient-Centered Care Through Wider Use of EHRs, CMS BLOG (Feb. 28, 2012),
http://blog.cms.gov/2012/02/28/stage-2-meaningful-use-nprm-moves-toward-patient-
centered-care-through-wider-use-of-ehrs/.
113. See CTRS. FOR MEDICARE & MEDICAID SERVS., Stage 2 Eligible Professional
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to identify educational resources tailored to the needs of specific
patients.114
Other objectives focus on facilitating patients' ability to obtain
their own data. Electronic health records must support the provision
of clinical care summaries to individual patients and allow patients to
download their own data."' The specific standards required for
achieving meaningful use reinforce these general objectives; one of
the measures of patient use, for example, is whether five percent of
patients actually view, use, or transmit their own records. 16
D. Health-Related Quality Reporting
A final example of a federal initiative in which a focus on making
data smaller is embedded within a broader goal of making data bigger
is health care quality reporting. As discussed in Part I, federal health
agencies have sought to collect health care quality-related data, to
aggregate public and private data so as to support the development of
better quality metrics, and to facilitate the sharing of data more
generally, some of which could be used in analyzing quality-related
issues.' Entities that access these data can use them to analyze
provider quality, which can be an important input into many different
sorts of decisions by health system stakeholders. Health care
providers may be interested in assessing their own quality relative to
their peers, while payers and policymakers may use the information
to get a better sense of the value of health care provided and how it
has changed over time. Sophisticated system stakeholders will often
have the tools to analyze these data on their own.
For individual patients who must select health care providers,
however, information about quality must be conveyed in a simple and
straightforward way in order to be usable. CMS has committed itself
to providing health care quality information for a growing number of
114. Id.
115. Id.
116. See CTRS. FOR MEDICARE & MEDICAID SERVS., Eligible Professional Meaningful
Use Core Measures: Measure 7 of 17, at 1 (2012), available at http://www.cms.gov
/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/downloads/Stage2
EPCore_7_PatientElectronicAccess.pdf. Another Stage 2 meaningful use core measure
requires providers to use secure electronic messaging to communicate with more than five
percent of patients. CrRS. FOR MEDICARE & MEDICAID SERVS., Eligible Professional
Meaningful Use Core Measures: Measure 17 of 17, at 1 (2012), available at http://www.cms
.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/downloads/Stage2
_EPCore_17_UseSecureElectronicMessaging.pdf.
117. See supra Parts I.B-I.D.
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types of health care providers.118 Its systematic, web-based health care
quality reporting began in 2005 with the publication of ten quality
measures for hospitals across the country."' In 2008, it added patient
experience ratings based on data from the Hospital Consumer
Assessment of Healthcare Providers survey, as well as information
about mortality rates for heart attacks, heart failures, and
pneumonia.120 Since then, it has added a number of other hospital
quality measures, including hospital readmissions.121 CMS also
provides quality ratings for nursing homes, home health agencies, and
dialysis facilities. 122 Individual patients can visit these websites, type in
their zip codes, and view quality measures associated with the nearest
providers. 123
Evidence suggests that the number of individuals actually using
quality ratings is relatively limited. A 2012 survey found that the
percentage of respondents who had consulted online rankings or
reviews of doctors and hospitals was in the range of fifteen percent,
with the most educated and the middle aged being disproportionately
more likely to consult such ratings.124 Nevertheless, the growth of
federally sponsored quality reporting continues. The ACA, for
example, mandated public reporting of physician quality information,
along with quality reporting in other areas.125 Authors of a recent
report examining the ACA's focus on patient-centeredness identify
nine distinct ACA provisions that require the use of measures of
patient-centered care, four of which involve public reporting.126
118. See supra notes 42-46, 52-54, 88-89 and accompanying text.
119. See Hospital Compare, CENTERS FOR MEDICARE & MEDICAID SERVICES,
https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments
/HospitalQualitylnits/HospitalCompare.html (last visited May 7, 2014).
120. Id.
121. Id.
122. See Quality Care Finder, MEDICARE.GOV, http://www.medicare.gov/quality-care-
finder/ (last visited May 7, 2014).
123. See, e.g., Hospital Compare, MEDICARE.GOV, http://www.medicare.gov/hospital
compare/search.html (last visited May 7, 2014).
124. SUSANNAH Fox & MAEVE DUGGAN, PEW RESEARCH CTR., HEALTH ONLINE
2013, at 20-23 (Jan. 2013), available at http://www.pewinternet.org/-/media//Files
[Reports/PIP HealthOnline.pdf (reporting the frequency of consulting online reviews
overall and within certain demographic groups based on 2010 and 2012 surveys). For more
discussion of earlier evidence on use of ratings, see Kristin Madison, The Law and Policy
of Health Care Quality Reporting, 31 CAMPBELL L. REV. 215, 220-23 (2009) [hereinafter
Madison V].
125. See Madison III, supra note 39, at 79-80.
126. MILLENSON & MACRI, supra note 98, at 7.
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Consumers have stressed that the usability of quality reporting
hinges on a simple presentation of information.127 The complexity of
quality metrics-especially when combined with the complexities of
the health care system and the medical conditions prompting patients
to seek ratings in the first place-can quickly overwhelm patients.
CMS has therefore sought to make quality data smaller not just by
producing quality metrics from its vast troves of data, but also by
streamlining its presentation of these metrics.128 One way it has done
so is by producing star ratings rather than just presenting statistical
data. For nursing home care, for example, CMS presents ratings such
as "above average" or "much below average," accompanied by
ratings on a five-star scale; more detail is available only with
additional clicks of a mouse. 29 CMS also provides star ratings for
Medicare Advantage plans and Medicare drug plans in which some
Medicare beneficiaries choose to enroll. 13 0 In 2012, CMS decided to
make data even smaller for Medicare beneficiaries by sending
enrollees of health and drug plans rated "poor" or "below average"
for at least three years a personal letter stating, "We encourage you
to compare this plan to other options in your area and decide if it is
still the right choice for you."'3 '
In all of these examples, federal agencies have fostered the
growth of data as part of their broader efforts to reform the health
care system. Expanding medical research, increasing knowledge
about the effectiveness of health-related interventions, building an
electronic health record infrastructure, and increasing information
about provider quality are all important ways that federal agencies
have contributed to the data that will undergird future health care
system operations. By extracting from these data-building initiatives
information that is potentially relevant to patient decision making-
127. See generally Value Judgment: Helping Health Care Consumers Use Quality and
Cost Information, CAL. HEALTHCARE FOUND. (Dec. 2012), available at http://www.ncqa
.org/portals/O/Public%2OPolicy/CHCF%20ValueJudgmentQualityCostlnformation.pdf
(exploring patients' use of quality information through focus groups).
128. See, e.g., Nursing Home Compare, MEDICARE.GOv, http://www.medicare.gov
/nursinghomecompare/search.html (last visited May 7, 2014) (using search function in
which a user types in ZIP Code or City, State and clicks Search).
129. See id.
130. Plan Quality and Performance Ratings, MEDICARE.GOv, http://www.medicare.gov
/find-a-plan/results/planresults/planratings/compare-plan-ratings.aspx?PlanType=MAPD
(last visited May 7, 2014) (prompting users to enter plan information to compare star
ratings for Advantage and drug plans).
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by making data smaller-these agencies have helped to ensure that
patients can exercise more influence over their own care and play a
more significant role in shaping the future health care system.
III. REMAKING DATA
Making data bigger and making data smaller are both important
steps toward facilitating better decision making. More data, and more
usable data, are beneficial for many different health system
stakeholders. But careful thought should also be given to the nature
of data being generated and the purposes these data serve.
Many of the previously discussed examples of data stewardship
were useful for decision making by private actors. Federal research
funding and data aggregation initiatives could change treatment
decisions made by private physicians and coverage decisions made by
private insurers.13 2 Mandates to collect and report data about aspects
of health care delivery may alter providers' decision making about the
care they provide and patients' decision making about the care they
receive.'33 Many federal data initiatives, including the HITECH
statute's facilitation of electronic health records'34 and all of the
initiatives to make data smaller, reduce the costs of information
acquisition, analysis, and use for all system stakeholders. HITECH
could facilitate the work of health care providers, streamline health
insurance claims processing, and greatly lower the costs facing health
care researchers. PCORI's projects will ultimately facilitate patients'
decision making.
The potential impact of the federal government's data
stewardship efforts, however, is not limited to their influence on
private individuals and entities. Information can be as valuable for
government decision makers as it is for private decision makers.
Medicare claims data are of course critical to the daily "decisions"
132. See Guy Boulton, Group Seeks Medicare Data to Increase Health Care Efficiency,
MILWAUKEE J. SENTINEL (Jan. 11, 2014), http://www.jsonline.com/business/group-seeks-
medicare-data-to-increase-health-care-efficiency-b99181177zl-239783441.html (describing
a state-based group's call for better access to Medicare claims data as a tool for improving
efficiency); COMMONWEALTH FUND COMM'N ON A HIGH PERFORMANCE HEALTH SYS.,
THE PATH TO A HIGH PERFORMANCE U.S. HEALTH SYSTEM, 48-55 (Feb. 2009)
(describing how building a better information infrastructure can help improve the U.S.
health care system).
133. See ROBERT A. BERENSON, PETER J. PRONOVOST & HARLAN M. KRUMHOLZ,
URBAN INST., ACHIEVING THE POTENTIAL OF HEALTH CARE PERFORMANCE
MEASURES 5-6 (2013), available at http://www.rwjf.org/content/dam/farm/reports/reports
/2013/rwjf406195 (describing the impact of quality reporting); Madison V, supra note 124,
at 220-26 (discussing empirical evidence on the impact of quality report cards).
134. See supra notes 74-84 and accompanying text.
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made by Medicare about whom to pay and how much, as is the
information about quality that now finds its way into federal payment
formulas.13 s But the sphere of public decision making extends far
beyond the mundane operations of public insurance programs.
Congress and federal agencies make countless legislative and
regulatory decisions that have a profound effect on the health care
system and ultimately on population health. These decisions, like the
decisions made by private providers, would also benefit from careful
data stewardship.
Federal agencies regularly make use of the data they collect to
analyze the effects of their own programs. The Government
Accountability Office, for example, recently used Medicare claims
data to investigate the implications of physician ownership of imaging
equipment for the frequency of imaging.136 This study's results added
to the evidence policy makers might take into account as they
consider the appropriate scope of the prohibitions and exceptions of
the Stark law,"' which limits the financial relationships among
referring physicians and providers of certain health care services. 8
There are many other examples of data collected in connection with
program operations being used in identifying program issues and
analyzing potential program reforms.'39 Among the institutions
created by the ACA was the Center for Medicare and Medicaid
Innovation ("Innovation Center"), which was charged with the task
of "test[ing] innovative service and delivery models to reduce
program expenditures ... while preserving or enhancing the quality
of care."'40 The Innovation Center will be heavily involved in
135. See Linking Quality to Payment, MEDICARE.GOV, http://www.medicare.gov
/hospitalcompare/linking-quality-to-payment.html (last visited May 7, 2014) (describing
the hospital readmissions reduction program and the hospital value-based purchasing
program).
136. See generally U.S. Gov'T ACCOUNTABILITY OFFICE, GAO-12-966, HIGHER USE
OF ADVANCED IMAGING SERVICES BY PROVIDERS WHO SELF-REFER COSTING
MEDICARE MILLIONS (2012), available at http://www.gao.gov/assets/650/648988.pdf
(analyzing Medicare data to assess the impact of self-referrals).
137. 42 U.S.C. § 1395nn (2012) (establishing limitations on certain physician referrals).
138. See Promoting Integrity in Medicare Act of 2013, H.R. 2914, 113th Cong. (2013).
139. See generally MEDICARE PAYMENT ADVISORY COMM'N, REPORT TO THE
CONGRESS: MEDICARE AND THE HEALTH CARE DELIVERY SYSTEM (June 2013),
available at http://www.medpac.gov/documents/Junl3_EntireReport.pdf (presenting data
on Medicare and discussing possible reforms).
140. 42 U.S.C. § 1315a(a)(1).
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analyzing data generated in connection with new models of service
141delivery and payment within public programs.
While claims data can be useful for decision-making purposes,
data initiatives specifically designed to elicit data relevant for
regulatory decision making would be even more helpful. Such
initiatives are rare. The information void is particularly apparent in
settings outside of public payment programs, where regulators do not
have pre-existing databases to draw from when making regulatory
decisions. The ACA imposes many new health-related obligations
and limitations: it requires calorie labeling on chain restaurant
menus,142 it mandates that drug and device manufacturers disclose
financial relationships with physicians, 143 and it limits employers' use
of financial incentives to encourage healthy behaviors.'" What it does
not do is establish federal programs to systematically collect data that
would allow federal regulators to predict or assess the impact of the
requirements they impose. Federal health agencies have devoted
considerable attention to expanding data for use by a variety of
decision makers and to distilling data for use by patients and others,145
but historically they seem to have devoted less attention to generating
data for their own use in regulatory decision making.
Federal agencies have long sought to assess the likely impact of
regulations before enactment; executive orders require regulators
proposing new, economically significant regulations to conduct
analyses of the regulations' likely costs and benefits. 4 6 These analyses
reflect agencies' predictions of regulatory consequences, based on
evidence drawn from a variety of sources.147 Recently, there has been
141. See William Shrank, The Center for Medicare and Medicaid Innovation's Blueprint
for Rapid-Cycle Evaluation of New Care and Payment Models, 32 HEALTH AFF. 807, 807-
09 (2013).
142. See 21 U.S.C. § 343(q)(5)(H) (2012).
143. See 42 U.S.C. § 1320a-7h(a).
144. See id. § 300gg-4(j).
145. See supra Parts 1, II.
146. See, e.g., Exec. Order No. 13563, 76 Fed. Reg. 3821, 3821 (Jan. 21, 2011); Exec.
Order No. 12866, 58 Fed. Reg. 51,735, 51,736 (Oct. 4, 1993). The Office of Information
and Regulatory Affairs ("OIRA") provides detailed guidance about how such analyses
should be conducted. For a recent example of such guidance, see generally OFFICE OF
MGMT. & BUDGET, REGULATORY IMPACT ANALYSIS: A PRIMER (Aug. 2011), available
at http://www.whitehouse.gov/sites/default/files/omb/inforeg/regpol/circular-a-4_regulatory
-impact-analysis-a-primer.pdf.
147. See OFFICE OF MGMT. & BUDGET, supra note 146, at 2 (agencies must provide "a
careful and transparent analysis of the anticipated consequences of economically
significant regulatory actions"); id. at 3 (the agency should use "the best available
scientific, technical, and economic information" and "generally rely on peer-reviewed
literature").
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more emphasis on the need to systematically assess regulations after
they have been put in place.148 An executive order from 2011 states as
a general principle that "[o]ur regulatory system ... must measure,
and seek to improve, the actual results of regulatory requirements."'49
It requires agencies to "consider how best to promote retrospective
analysis of rules that may be outmoded, ineffective, insufficient, or
excessively burdensome" and to develop "a preliminary plan ...
under which the agency will periodically review its existing significant
regulations."' Cass Sunstein has emphasized the importance of
assessing regulations' actual effects, both intended and unintended.,'
Efforts to engage in some form of retrospective evaluation have
begun; hundreds of regulatory reviews have already been
completed. 52 Cary Coglianese criticizes these retrospective reviews,
however, as being "ad hoc and largely unmanaged."153 To foster more
systematic review, he proposes, among other steps, the adoption of a
requirement that agencies "include in each prospective regulatory
impact analysis" conducted as part of the regulatory process "a plan
for the subsequent evaluation of the proposed rule."l54 This plan
should specify metrics that could be used to assess whether regulatory
objectives were met, to identify existing data or propose data that
could be developed for use in the assessment, and to discuss potential
research designs (including "sources of cross-sectional or longitudinal
variation, other potential explanatory factors that might need to be
controlled, and possible statistical approaches to estimating
counterfactuals").15 5
Coglianese's proposal is ambitious. Researchers in many fields
can testify to the practical and financial barriers involved in
identifying or developing relevant data and settling on appropriate
148. For a general discussion of regulatory impact analysis, including the executive
orders guiding it, see Cass R. Sunstein, Empirically Informed Regulation, 78 U. CHI. L.
REV. 1349, 1387-92 (2011).
149. Exec. Order No. 13563, 76 Fed. Reg. at 3821.
150. Id. at 3822. An executive order from 2012 reinforces these requirements and calls
for further steps to be taken. See Exec. Order No. 13610, 77 Fed. Reg. 28,469, 28,469 (May
14, 2012).
151. Sunstein, supra note 148, at 1389 ("[Rlegulations should be revisited and reviewed
retrospectively, to ensure that they are promoting their intended functions, and are not
producing excessive costs or unintended adverse side effects.").
152. Cary Coglianese, Moving Forward with Regulatory Lookback, 30 YALE J. ON
REG. 57, 58 (2013).
153. Id. at 59.
154. Id. at 62.
155. Id. at 62-63.
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research methodologies. 5 6 Assessing an intervention that occurs
outside of a controlled environment, and that is thus subject to many
confounding factors, is particularly challenging. The advantage of
developing such research plans, however, whether done in
conjunction with issuing a proposed regulation or even earlier, when
the possibility of future regulation becomes apparent, is that it would
allow for a much more robust assessment of potential regulatory
impacts.
Both Coglianese and Sunstein cite to the work of Michael
Greenstone,"' who has called for a "move toward a culture of
persistent regulatory experimentation."' Making an analogy to the
FDA's drug approval process, Greenstone stresses the need for
greater testing of regulations."' He calls for more funding for
evaluations and the creation of an independent review board that
would assess the effectiveness of regulations.16 Greenstone also calls
for small-scale implementation of regulations, which would
accommodate the variation necessary to allow rigorous testing of the
effects of regulation.' 1 He refers briefly to the possibility of quasi-
experiments or randomized controlled trials of regulations,'162 an idea
that has been advocated as potentially feasible by policy groups' and
explored by other legal scholars." Sunstein notes that randomized
experiments have "particular advantages" and that "experimental or
quasi-experimental studies are preferred to focus groups," although
focus groups can sometimes be useful in assessing regulations.' 65
156. See, e.g., Austin Nichols, Causal Inference with Observational Data, 7 STATA J.
507, 507-08 (2007), available at http://www.stata-journal.com/sjpdf.html?articlenum
=st0136 (describing challenges of causal inference and possible methodological
alternatives to randomized controlled trials).
157. Coglianese, supra note 152, at 60 (citing Greenstone for a proposal to create a
regulatory institution focused on retrospective review); Sunstein, supra note 148, at 1391-
92 (discussing Greenstone's insights on regulatory experimentation).
158. Michael Greenstone, Toward a Culture of Persistent Regulatory Experimentation
and Evaluation, in NEW PERSPECTIVES ON REGULATION 111, 112 (David Moss & John
Cisternino eds., 2009).
159. See id.
160. See id. at 119-21.
161. See id. at 118-19.
162. Id. at 119.
163. See, e.g., COAL. FOR EVIDENCE-BASED POLICY, RIGOROUS PROGRAM
EVALUATIONS ON A BUDGET 3 (Mar. 2012), available at http://coalition4evidence.org
/wordpress/wp-content/uploads[Rigorous-Program-Evaluations-on-a-Budget-March-
2012.pdf.
164. See, e.g., Michael Abramowicz, Ian Ayres & Yair Listokin, Randomizing Law, 159
U. PA. L. REV. 929,948 (2011).
165. Sunstein, supra note 148, at 1371.
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In an ideal world, regulators would have access to data that
would allow them to test potential regulations before they are
implemented, as well as to continuously collect data that would allow
them to monitor post-implementation effects. The executive order
calling for retrospective analysis of rules "that may be outmoded,
ineffective, insufficient, or excessively burdensome" is a step forward,
but as Coglianese suggests, it would be useful to develop study
methodologies and data collection plans prospectively." In addition,
the executive order's call for retrospective review sounds somewhat
akin to the FDA's requirements for the evaluation of safety and
effectiveness of a drug, where the goal is to see if the drug works and
what its problematic side effects might be,167 rather than to determine
what drug works best. In an ideal world, regulatory evaluation would
push toward the comparative evaluation now stressed in the health
care setting. We do not want to know only whether a regulation
works; we want to know which regulation works best.
To develop the informational foundation necessary for both
prospective and retrospective evaluation, agencies must structure
regulations to facilitate appropriate data generation, and Congress
must give them authority to do so. In another article, I explore some
mechanisms that federal agencies could potentially use to generate
useful data in the health context. 1 68 One possibility is the conditioned
waiver: a waiver of existing regulations that would allow regulated
entities to undertake otherwise prohibited activities, provided that
they supply data that permits assessment of the impact of the
waiver. Another possibility is regulating with variation, such as by
allowing federal regulators to test the impact of restaurant menu
labeling regulations by imposing different requirements in different
geographic areas and/or by changing regulations in a systematic way
over time.170
A third possible approach that could provide at least some
helpful data to regulators would be to make greater use of regulations
that condition activities on detailed reporting. In other work, I have
discussed recent regulations of employer health plans that make use
166. Coglianese, supra note 152, at 62-63 (proposing development of evaluation plans).
167. See 21 C.F.R. §§ 312.21-312.22 (2013) (describing phases of clinical trials for
investigational new drugs); Development & Approval Process (Drugs), FOOD & DRUG
ADMIN., http://www.fda.gov/Drugs/DevelopmentApprovalProcess/default.htm (last
updated Oct. 23, 2013) (describing the drug approval process).
168. See Kristin Madison, Building a Better Laboratory: The Federal Role in Promoting
Health System Experimentation, 41 PEPP. L. REV 765 (2014).
169. See id. at 806-14.
170. See id. at 800-06.
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of financial incentives contingent on health standards, such as
premium discounts for individuals with a body mass index below a
certain threshold."' Rather than simply raising the ceiling on the
magnitude of incentives, regulators could condition the use of high
levels of incentives on the disclosure of information that would give
regulators more information about these programs, even if it is not
enough to conduct a full evaluation. 17 2 This approach would be less
costly to regulated entities than a blanket reporting requirement, but
it might still generate data that is useful in assessing whether further
regulation might be warranted.
The prospect of systematically collecting information to support
regulatory evaluation seems daunting, but there are some efforts
underway to do so. In 2012, the Office of Management and Budget
("OMB") issued a memo that directs agencies to "include a separate
section" in their budget submissions "on agencies' most innovative
uses of evidence and evaluation" and notes that "[t]he Budget also
will allocate limited resources for initiatives to expand the use of
evidence."' The memo calls for the implementation of evaluations
using administrative data and evaluations linked to waiver
authorities, among other steps, to encourage more evidence-based
policy making.'7 4 While recognizing the existence of legal, financial,
and practical constraints of randomized trials of regulations, the
Departments of Treasury, Labor, and Interior have all stated that
they will consider using experimental designs to determine the impact
of regulations. 7 '
One example of a commitment to regulatory assessment is found
in the recently established Tobacco Centers of Regulatory Science,
which will not just "increase understanding of the risks associated
with tobacco use," but also "aid in ... evaluation of tobacco product
regulations" and "help . . . assess the impact of FDA's prior, ongoing,
and potential future tobacco regulatory activities."'7 6 But perhaps the
171. See Kristin Madison, Harald Schmidt & Kevin G. Volpp, Using Reporting
Requirements to Build an Evidence Base to Improve Employer Wellness Incentives and
Their Regulation, 39 J. HEALTH POL. POL'Y & L. (forthcoming 2014).
172. Id. (manuscript at 1-2).
173. Memorandum from the Office of Mgmt. & Budget to the Heads of Exec. Dep'ts
and Agencies 1 (May 18, 2012), available at http://www.whitehouse.gov/sites/default/files
/omb/memoranda/2012/m-12-14.pdf.
174. Id. at 1-2.
175. See Sunstein, supra note 148, at 1392.
176. Press Release, Nat'1 Insts. of Health, FDA and NIH Create First-of-Kind Tobacco
Centers of Regulatory Science (Sept. 19, 2013), available at http://www.nih.gov/news
/health/sep2013/od-19.htm.
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clearest example of a statutory and regulatory framework that
supports systematic assessment is that associated with the Consumer
Financial Protection Bureau (the "Bureau").'77 In creating the
Bureau, Congress established a regulatory framework structured to
permit systematic collection of data, encourage prospective
regulatory experimentation, and require retrospective regulatory
evaluation. Congress required the Bureau to monitor the risks posed
to consumers in the financial product and service markets and
granted the Bureau the authority to "gather and compile information
from a variety of sources," including surveys and database reviews,
and to require certain entities "to file . . . annual or special reports, or
answers in writing to specific questions . . . as necessary for the
Bureau to fulfill the monitoring, assessment, and reporting
responsibilities imposed by Congress.""' In other words, Congress
mandated systematic collection of data in an area in which the
Bureau had the authority to regulate-data that the Bureau could
potentially use to lay the foundation for future regulation.
In addition, Congress gave the Bureau authority to permit
experimentation. More specifically, it granted authority to allow trial
disclosure programs in which covered entities would be permitted to
attempt to "improve upon any model form" issued by the Bureau.7 9
In essence, this authority allows regulated entities to propose their
own experiments. The Bureau has expressed a willingness to
authorize such experiments if the information they produce will be
helpful.'s In a policy notice issued in 2013, the Bureau notes that "in-
market testing, involving companies and consumers in real world
situations, may offer particularly valuable information with which to
improve disclosure rules and model forms."'' To obtain a waiver of
otherwise applicable federal disclosure requirements, companies must
test whether disclosure has indeed improved areas such as consumer
use or understanding, and share this data with the Bureau.18
177. The author thanks Melissa Jacoby for suggesting this example.
178. 12 U.S.C. § 5512(c)(4) (2012).
179. Id. § 5532(e)(1). In fact, the statute pushes the Bureau to not just allow, but
encourage trial disclosures; the statute states that "standards and procedures issued by the
Bureau shall be designed to encourage covered persons to conduct trial disclosure
programs." Id. § 5532(e)(2).
180. Among the criteria used for granting waiver approval is the extent to which the
proposed program will help the Bureau improve its disclosure rules. See Policy to
Encourage Trial Disclosure Programs, 78 Fed. Reg. 64,389, 64,393 (Oct. 29, 2013) (policies
B.1 and B.2).
181. Id. at 64,389.
182. Id. at 64,393 (policies A.3 and A.9).
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Finally, within five years of a significant rule's effective date,
Congress has required the Bureau to assess the rule's effectiveness in
meeting statutory objectives and the Bureau's goals based on
"available evidence and any data that the Bureau reasonably may
collect."18 3 Together, these three aspects of the statutory framework
undergirding the Bureau-the authorization and requirement to
collect data, the waiver authority that would allow at least some
variation in regulations, and the requirement for retrospective
evaluation-ensure a long-term role for the Bureau as a data steward.
Similar authorities and requirements could be put in place for health
agencies.
The ultimate scope and impact of the Bureau's data stewardship
remain to be seen. Data collection and waiver authorities can be used
sparingly or expansively; retrospective analyses may vary in their
comprehensiveness. Nevertheless, the very existence of these data
stewardship functions reflects a federal interest in developing and
using new data sources to better inform the regulatory process. This
orientation toward purposeful data collection and analysis is
consistent with recent calls for retrospective regulatory evaluation,
and if it is more broadly embraced by health regulators, it will provide
a firmer foundation for future health-related regulation. By reshaping
the data environment surrounding health regulatory functions-by
remaking data-health-related agencies would be better positioned to
ensure that their regulatory efforts are well spent.
CONCLUSION
It is apparent that the federal government's role as a health data
steward is rapidly growing. Numerous federal initiatives have focused
on expanding data in ways that could ultimately be used by public and
private payers to transform the health care system. At the same time,
federal entities have embraced a commitment to distilling vast
quantities of data into much smaller amounts of information tailored
for and targeted to the needs of individuals. However, much remains
to be done to cultivate data that could be used not just by external
health system stakeholders or patients, but internally, by agencies
themselves, to evaluate actual or proposed regulations. As health
data stewards, federal agencies have an obligation to identify ways to
gather the data necessary to support this critical function.
183. 12 U.S.C. § 5512(d).
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